Ceryvyn Therapeutics Limited, a biopharmaceutical company, develops biologic therapy for the rare disease lymphangioleiomyomatosis in Australia. The company offers CYV-101, which is in pre-clinical trial stage, an inhaled therapy intended for delivery directly to the lung. It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Hawthorn East, Australia.
Frequently asked questions
What sector does Opthea Ltd (CKDXF) operate in?
Opthea Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Opthea Ltd (CKDXF) current stock price?
As of the latest data, Opthea Ltd stock price is $0.01, with a previous close of $0.01.
What is Opthea Ltd (CKDXF) current market capitalization?
Opthea Ltd market cap is approximately 14.64 million.
What is Opthea Ltd (CKDXF) Earnings Per Share (EPS)?
The trailing EPS is $0.18.
What is Opthea Ltd (CKDXF) Price-to-Earnings (P/E) ratio?
Opthea Ltd current P/E ratio is 0.06.
What is Opthea Ltd (CKDXF) EBITDA?
Opthea Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.38 million.
Does Opthea Ltd (CKDXF) pay dividends?
No. Opthea Ltd does not pay a dividend.
What is Opthea Ltd (CKDXF) beta (volatility) score?
Opthea Ltd has a beta of 1.489, suggesting it is more volatile than the market.